Synaptogenix (SNPX) Competitors $6.93 -0.03 (-0.43%) As of 08/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. FGEN, NBRV, TPST, SLGL, GRCE, GBIO, TELO, JSPR, ATHE, and ACRVShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include FibroGen (FGEN), Nabriva Therapeutics (NBRV), Tempest Therapeutics (TPST), Sol-Gel Technologies (SLGL), Grace Therapeutics (GRCE), Generation Bio (GBIO), Telomir Pharmaceuticals (TELO), Jasper Therapeutics (JSPR), Alterity Therapeutics (ATHE), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors FibroGen Nabriva Therapeutics Tempest Therapeutics Sol-Gel Technologies Grace Therapeutics Generation Bio Telomir Pharmaceuticals Jasper Therapeutics Alterity Therapeutics Acrivon Therapeutics FibroGen (NASDAQ:FGEN) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings. Do analysts rate FGEN or SNPX? FibroGen presently has a consensus price target of $43.00, indicating a potential upside of 287.74%. Given FibroGen's stronger consensus rating and higher probable upside, equities analysts clearly believe FibroGen is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, FGEN or SNPX? FibroGen has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Which has preferable valuation & earnings, FGEN or SNPX? Synaptogenix has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$29.62M1.51-$47.58M-$0.38-29.18SynaptogenixN/AN/A-$12.77M-$10.08-0.69 Does the media refer more to FGEN or SNPX? In the previous week, FibroGen had 8 more articles in the media than Synaptogenix. MarketBeat recorded 8 mentions for FibroGen and 0 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.00 beat FibroGen's score of -0.01 indicating that Synaptogenix is being referred to more favorably in the news media. Company Overall Sentiment FibroGen Neutral Synaptogenix Neutral Is FGEN or SNPX more profitable? Synaptogenix has a net margin of 0.00% compared to FibroGen's net margin of -3.86%. FibroGen's return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets FibroGen-3.86% N/A -27.34% Synaptogenix N/A -115.28%-58.31% Do insiders & institutionals have more ownership in FGEN or SNPX? 72.7% of FibroGen shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 3.1% of FibroGen shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryFibroGen beats Synaptogenix on 10 of the 15 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.63M$3.10B$5.76B$9.60BDividend YieldN/A2.23%3.84%4.07%P/E Ratio-0.6920.1730.4025.20Price / SalesN/A378.67457.42115.66Price / CashN/A43.0937.1558.42Price / Book1.607.919.006.24Net Income-$12.77M-$54.72M$3.26B$265.30M7 Day Performance-27.51%1.66%1.06%-1.13%1 Month Performance-31.45%5.88%4.31%-0.71%1 Year Performance82.37%8.72%28.39%18.86% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenixN/A$6.93-0.4%N/A+85.6%$9.63MN/A-0.694Gap UpFGENFibroGen4.6015 of 5 stars$10.56-6.5%$43.00+307.2%+2.4%$45.70M$29.62M-27.79570Gap DownNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070TPSTTempest Therapeutics1.3156 of 5 stars$9.25-9.0%$30.00+224.3%-50.4%$45.11MN/A-0.6320SLGLSol-Gel Technologies1.0889 of 5 stars$17.74+10.2%N/A+309.8%$44.85M$11.54M-14.4250News CoveragePositive NewsEarnings ReportGap UpGRCEGrace Therapeutics2.8387 of 5 stars$3.29+1.9%$12.00+264.7%N/A$44.72MN/A-3.83N/AGBIOGeneration Bio3.3025 of 5 stars$6.39-3.6%$10.67+66.9%-75.6%$44.66M$21.23M-0.59150Analyst ForecastTELOTelomir Pharmaceuticals2.1448 of 5 stars$1.47-1.3%$15.00+920.4%-72.5%$44.35MN/A-2.721Earnings ReportJSPRJasper Therapeutics2.9246 of 5 stars$2.85-2.7%$28.75+908.8%-84.8%$44.01MN/A-0.4720Analyst RevisionATHEAlterity Therapeutics2.2414 of 5 stars$4.95-5.2%$12.00+142.4%+269.9%$43.89MN/A0.0010ACRVAcrivon Therapeutics2.938 of 5 stars$1.30-6.5%$17.57+1,251.6%-85.6%$43.72MN/A-0.5858Analyst RevisionGap Down Related Companies and Tools Related Companies FibroGen Alternatives Nabriva Therapeutics Alternatives Tempest Therapeutics Alternatives Sol-Gel Technologies Alternatives Grace Therapeutics Alternatives Generation Bio Alternatives Telomir Pharmaceuticals Alternatives Jasper Therapeutics Alternatives Alterity Therapeutics Alternatives Acrivon Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access